Antigua Breaking News

Top Trusted News Source in Antigua

Search
Previous slide
Next slide

Autoimmune disorder warning added to AstraZeneca, J&J vaccines

Share this article:

Facebook
Twitter
Pinterest
LinkedIn

Health Canada is updating the labels for the AstraZeneca and Johnson & Johnson COVID-19 vaccines to add immune thrombocytopenia (ITP), an autoimmune condition, as a potential side effect.

In a statement on Tuesday, the agency said very rare cases of ITP have been reported internationally after receiving the Vaxzevria (AstraZeneca) and Janssen (J&J) COVID-19 vaccines.

ITP is a disorder that can cause easy or excessive bruising and bleeding, which results from unusually low blood platelet levels.

Such cases typically occur within 28 days after vaccination, the agency said. Deaths as a result of post-vaccination ITP have been reported outside of Canada. Some cases occurred in individuals who had a prior history of the disorder.

Both the AstraZeneca and J&J vaccines have been approved for use in Canada and are deemed safe and effective.

The agency advised Canadians to seek immediate medical attention if any of the following symptoms occurred after receiving the AstraZeneca and J&J shots:

Be part of the conversation.

Let us know what you think by adding a comment below. Click here to start now!

  • unexplained bleeding
  • unexplained bruising
  • small purplish spots beyond the site of vaccination
  • shortness of breath
  • chest pain
  • leg pain and/or swelling
  • persistent abdominal pain.

Health Canada said if an individual has a history of a thrombocytopenic disorder, such as immune thrombocytopenia, the risk of developing low platelet levels should be considered before administering the vaccine and platelet monitoring is recommended after vaccination.

In its label update on Tuesday, the agency said there was also the rare risk of venous thromboembolism (VTE) – a type of blood clot that starts in the vein – following vaccination with the Johnson & Johnson vaccine.

More than 224,000 Canadians have received two doses of the AstraZeneca Vaxzevria COVID-19 vaccine and more than 9,000 have received the single-shot J&J vaccine.

In March, Health Canada added a warning about blood clots to the Oxford-AstraZeneca vaccine following several reports after immunization.

In June, the agency updated the label for the Oxford-AstraZeneca and Covishield COVID-19 vaccines to also add capillary leak syndrome as a potential side-effect. (Global News)

Share this article:

Facebook
Twitter
Pinterest
LinkedIn

Join the Conversation!

One response to “Autoimmune disorder warning added to AstraZeneca, J&J vaccines”

  1. This news item just goes to show that science has now become politicised. Money, and not our health – through this rushed vaccine policy – has been, the fast-tracked driving force from all the global politicians to control us.

    Despite the high rate of hospitalisation increasing amongst the FULY VACCINATED, politicians are still telling the world that this is the pandemic of the unvaccinated.

    Peter Doshi, who has a PhD in history, anthropology and science technology, is also a Senior Editor at the British Medical Journal (BMJ), and is part of the news & views team. Based in Baltimore, he is also an associate professor of Pharmaceutical Health Services research at the University of Maryland School of Pharmacy.

    Writing in the (BMJ), Peter Doshi highlights four things that now sheds light on the problems with vaccine data: 1), published claims that vaccines saved lives were based on JUST ONE DEATH in 70,000 Pfizer and Morderna trial participants. 2), clinical trials of Covid-19 vaccines have not shown any reductions in deaths. 3), the mRNA Covid-19 vaccines are qualitatively made different from traditional vaccines. 4), in January 2021, the dictionary definition of vaccines changed to encompass mRNA products.

    As Albert Einstein once said: “Blind belief in authority is the greatest enemy of truth”.

    This is why I am standing on the right side of history folks, as more lies and falsehoods are coming out.

    RESPECT TO ALL THOSE ANTIGUANS THAT ARE WELL READ, AND ARE CRITICAL THINKERS!

REQUEST FOR EXPRESSIONS OF INTEREST

(CONSULTING SERVICES – INDIVIDUAL SELECTION)

 

OECS MSME Guarantee Facility Project

Loan No.: IDA-62670, IDA-62660, IDA-62640, IBRD-88830, IDA-62650

Assignment Title: Senior Operating Officer (SOO)

Reference No. KN-ECPCGC-207852-CS-INDV

 

The Governments of Antigua and Barbuda, Commonwealth of Dominica, Grenada, St. Lucia and St. Vincent and the Grenadines have received financing in the amount of US$10 million equivalent from the World Bank towards the cost of establishing a partial credit guarantee scheme, and they intend to apply part of the proceeds to payments for goods, and consulting services to be procured under this project. 

The consultant will serve as the “Senior Operating Officer (SOO)” for the ECPCGC and should possess extensive knowledge of MSME lending with some direct experience lending to Micro, small and medium-sized businesses, knowledge of the internal control processes necessary for a lending operation and the ability to design and implement risk mitigation procedures. The ideal candidate should possess an Undergraduate Degree from a reputable college or university, preferably in Business, Accounting, Banking or related field, with a minimum of 5 years’ experience in lending, inclusive of MSME lending. The initial employment period will be for two years on a contractual basis. Renewal of the contract will be subject to a performance evaluation at the end of the contractual period. The assignment is expected to begin on September 30th, 2021.  The consultant will report directly to the Chief Executive Officer of the ECPCGC.

The detailed Terms of Reference (TOR) for the assignment can be viewed by following the attached link below. 

 

https://bit.ly/3iVannm

 

The Eastern Caribbean Partial Credit Guarantee Corporation (ECPCGC) now invites eligible “Consultants” to indicate their interest in providing the Services. Interested Consultants should provide information demonstrating that they have:

  • An Undergraduate Degree from a reputable college or university, preferably in Business, Finance, Banking or related field; and
  • Minimum of 5 years’ experience in MSME lending. Applicants should also have:
  • The ability to design and implement risk management procedures 
  • Extensive knowledge of MSME lending with some direct experience lending to small and medium-sized businesses
  • Extensive knowledge of MSME banking operations
  • Knowledge of the internal controls necessary for a lending operation and the ability to design and implement risk management procedures
  • Experience developing and presenting information in public, including responding to questions in real-time
  • Experience lending to MSMEs located in the ECCU
  • Knowledge of marketing and communicating with the MSME sector
  • Ability to draft procedures to be used in a lending operation
  • Familiarity with the mechanics of a loan guarantee program
  • Exceptional written, oral, interpersonal, and presentation skills, and
  • Proficiency in the use of Microsoft Office suite.

The attention of interested Individual Consultants is drawn to Section III, Paragraphs 3.14, 3.16, and 3.17 of the World Bank’s Procurement Regulations for IPF Borrowers July 2016, [revised November 2017] (“Procurement Regulations”), setting forth the World Bank’s policy on conflict of interest. A Consultant will be selected in accordance with the Approved Selection Method for Individual Consultants set out in the clause 7.34 of the World Bank Procurement Regulations for IPF Borrowers. 

 

Further information can be obtained at the address below during office hours 0800 to 1700 hours:

Eastern Caribbean Partial Credit Guarantee Corporation

Brid Rock, Basseterre,

St. Kitts.

Expressions of interest must be delivered in a written form by e-mail by August 11th, 2021, to [email protected]

 

For further information, please contact:

Carmen Gomez-Trigg                                                            Bernard Thomas

Chief Executive Officer                                                          Chief Financial Officer

Tel: 868-620-8144                                                                  Tel: 869-765-2385

Email: [email protected]                                          [email protected]